2020年东盟制药报告：2020年及以后制药行业的机遇与威胁 - 亚洲制药原料展览会（英文版）（16页）.pdf

1、ASEAN Pharma Report: Opportunities in particular, as price controls across the region prevent increased costs being passed onto patients. As a result, increasing regional and international sale approaches are being sorted. This is 3ASEAN Pharma Report | CPhI South East Asia Opportunities and threats

2、 2020 and beyond especially the case among the few manufacturers that have achieved PIC/S standards. Of the major regional economies, Indonesia and Thailand with the introduction of GMP standards becoming wider spread appear to have the best short-term potential to support generics-led export growth

3、 strategies. Growing Focus on R with tier 1-2 generics required to be manufactured to EU-GMP or PIC/S-GMP standards. Estimates suggest that hospitals accounted for 75% of Vietnams pharmaceutical industry revenue in 2019, equating to around $4.9bn of the $6.5bn total. The number of EU-GMP and PIC/S-G

4、MP facilities in Vietnam is a serious problem curtailing the two key growth pathways noted above. It is here that investment opportunities for foreign companies present themselves as domestic companies looking for partners to help transform production technology. A recent example includes Germanys S

5、TADA who invested a 72% indirect shareholding in Vietnams Pymepharmcov, which owns oneof the 17 accredited facilities. However, several countries in the ASEAN region are now members of the Pharmaceutical Inspection Co-operation Scheme, which aims to harmonise inspection procedures across the globe b

6、y developing common GMP standards, providing training opportunities to inspectors, and facilitating co-operation between both regional and international organisations. In addition to Singapore, Malaysia and Indonesia joined the scheme in 2002 and 2012 respectively, whilst Thailand joined in 2016, an